FrancophonIA/ELRC3.0 huggingface dataset:
English: Administration of ciclosporin 3 hours after lercanidipine yielded no change of the lercanidipine AUC, but the ciclosporin AUC was increased by 27%.
Croatian: AUC-a lerkanidipina, ali AUC ciklosporina povećao se za 27%.
English: • High level of lipids in your blood.
Croatian: • lipide (masnoće) u krvi.
English: Uncoloured glass (type I) ampoule.
Croatian: 6.5 Vrsta i sadržaj spremnika Ampula od bezbojnog stakla (tip I).
English: Rare side effects: These side effects may affect between 1 and 10 in every 10,000 people.
Croatian: Rijetke nuspojave: Ove se nuspojave mogu javiti između 1 i 10 na svakih 10 000 osoba.
English: if you have kidney problems.
Croatian: • ako imate tegobe s bubrezima.
English: DATE OF REVISION OF THE TEXT [To be completed nationally]
Croatian: DATUM REVIZIJE TEKSTA
English: Common side effects: These side effects may affect between 1 and 10 in every 100 people.
Croatian: Česte nuspojave: Ove se nuspojave mogu javiti u između 1 i 10 na svakih 100 osoba.
English: NAME OF THE MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally] {Name}
Croatian: Nositelj odobrenja za stavljanje gotovog lijeka u promet i proizvođač [Ispunjava država članica]
English: Patients on Sandimmun should not receive concomitant ultraviolet B irradiation or PUVA photochemotherapy.
Croatian: Bolesnici koji primaju Sandimmun ne smiju se istodobno liječiti ultraljubičastim
English: if you have liver problems.
Croatian: • ako imate tegobe s jetrom.
English: Uncommon side effects: These side effects may affect between 1 and 10 in every 1,000 people.
Croatian: Manje česte nuspojave: Ove se nuspojave mogu javiti između 1 i 10 na svakih 1000 osoba.
English: Renal dysfunction (see section 4.4) Reproductive system and breast disorders Rare
Croatian: Disfunkcija bubrega (vidjeti dio 4.4)
English: Capsule shell Iron oxide yellow (E172) Titanium dioxide (E171) Glycerol 85% Sorbitol syrup special Gelatin
Croatian: Ovojnica kapsule željezov oksid, žuti (E172) titanijev dioksid (E171) glicerol 85% sorbitol sirup, posebni želatina
English: if you have gout.
Croatian: • ako se trebate cijepiti.
English: In most cases, Sandimmun concentrate for solution for infusion is preferred for this purpose.
Croatian: Sandimmun koncentrat za otopinu za infuziju.
English: Care should be taken when using ciclosporin together with other active substances that exhibit nephrotoxic synergy such as: aminoglycosides (including gentamycin, tobramycin), amphotericin B, ciprofloxacin, vancomycin, trimethoprim (+ sulfamethoxazole); fibric acid derivatives (e.g. bezafibrate, fenofibrate); NSAIDs (including diclofenac, naproxen, sulindac); melphalan histamine H2-receptor antagonists (e.g. cimetidine, ranitidine); methotrexate (see section 4.4).
Croatian: bezafibrat, fenofibrat); NSAIL-ovi (uključujući diklofenak, naproksen, sulindak); antagonisti melfalan histamin H2-receptora (npr. cimetidin, ranitidin); metotreksat (vidjeti dio 4.4).
English: Capsule shell Iron oxide red (E172) Titanium dioxide (E 171) Glycerol 85% Sorbitol syrup special Gelatin
Croatian: Ovojnica kapsule željezov oksid, crveni (E172) titanijev dioksid (E 171) glicerol 85% sorbitol sirup, posebni želatina
English: Capsule shell Iron oxide red (E172) Titanium dioxide (E171) Glycerol 85% Sorbitol syrup special Gelatin
Croatian: Ovojnica kapsule željezov oksid, crveni (E172) titanijev dioksid (E171) glicerol 85% sorbitol sirup, posebni želatina
English: Talk to your doctor before taking Sandimmun: if you have or have had alcohol-related problems.
Croatian: Prije i tijekom liječenja Sandimmunom, odmah obavijestite svog liječnika: • ako imate bilo kakve znakove infekcije, kao što su vrućica i grlobolja.
English: Intravenous use
Croatian: Peroralna primjena
English: How to store Sandimmun
Croatian: Moguće nuspojave Kako čuvati Sandimmun
English: • Stomach ulcer.
Croatian: • Tegobe s jetrom.
English: No impairment in fertility was demonstrated in studies in male and female rats.
Croatian: U ispitivanjima na mužjacima i ženkama štakora nije bilo uočeno smanjivanje plodnosti.
English: Very common
Croatian: Često
English: Macrogolglycerol ricinoleate/polyethoxylated castor oil
Croatian: 6.1 Popis pomoćnih tvari etanol, bezvodni makrogolglicerolricinoleat/polietoksilirano ricinusovo ulje
English: Method of administration Oral use
Croatian: OBLIK Oralna otopina
English: What Sandimmun looks like and contents of the pack Sandimmun 25 mg soft capsules are pink and oval.
Croatian: Sandimmun 25 mg meke kapsule su ružičaste i ovalne.
English: The usual dose is 60 mg once a day.
Croatian: Uobičajena doza je 60 mg jedanput na dan.
English: Thrombin is essential for blood clotting.
Croatian: Trombin je neophodan za zgrušavanje krvi.
English: The full EPAR for Roteas can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Roteas nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This medicine is the same as Lixiana, which is already authorised in the European Union (EU).
Croatian: Taj je lijek isti kao i lijek Lixiana, koji je već odobren u Europskoj uniji (EU).
English: Bleeding can occur at any site and can be severe or even fatal.
Croatian: Do krvarenja može doći na bilo kojem dijelu tijela i ono može biti ozbiljno ili čak smrtonosno.
English: Other information about Roteas
Croatian: Ostale informacije o lijeku Roteas
English: This means that it blocks factor Xa, an enzyme that is involved in the production of thrombin.
Croatian: To znači da blokira faktor Xa, enzim koji sudjeluje u proizvodnji trombina.
English: What measures are being taken to ensure the safe and effective use of Roteas?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Roteas?
English: What is Roteas and what is it used for?
Croatian: Što je Roteas i za što se koristi?
English: The company that makes Lixiana has agreed that its scientific data can be used for Roteas (‘informed consent').
Croatian: Tvrtka koja proizvodi lijek Lixiana pristala je da se njezini znanstveni podatci upotrebljavaju za lijek Roteas („informirani pristanak”).
English: It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use.
Croatian: U njemu se objašnjava kako je Agencija ocijenila lijek da bi preporučila njegovo odobrenje u EU-u te uvjete za njegovu primjenu.
English: Roteas is available as tablets (15, 30 and 60 mg) and can only be obtained with a prescription.
Croatian: Lijek Roteas dostupan je u obliku tableta (od 15, 30 i 60 mg) i izdaje se samo na recept.
English: It must also not be used in pregnant or breastfeeding women or together with another anticoagulant.
Croatian: Ne smije se upotrebljavati za liječenje trudnica ili dojilja ili u kombinaciji s drugim antikoagulansom.
English: This is a summary of the European public assessment report (EPAR) for Roteas.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Roteas.
English: Roteas is an anticoagulant medicine (a medicine that prevents blood clotting) used in adults:
Croatian: Roteas je antikoagulans (lijek koji sprječava zgrušavanje krvi) koji se koristi u odraslih osoba:
English: The effects were studied in one main study, which involved over 21,000 patients for an average of 2.5 years.
Croatian: Učinci su ispitivani u jednom glavnom ispitivanju na više od 21 000 bolesnika tijekom prosječno 2,5 godina.
English: Further episodes were seen in 130 of 4,118 patients given edoxaban (3.2%) and in 146 of 4,122 given warfarin (3.5%).
Croatian: Daljnje epizode primijećene su kod 130 od 4 118 bolesnika koji su primali edoksaban (3,2 %) i kod 146 od 4 122 bolesnika koji su primali varfarin (3,5 %).
English: Although there was greater a risk of bleeding from the mucosa (tissues lining body cavities such as the nose, gut and vagina), the Committee considered that the risk could be managed with appropriate measures.
Croatian: Iako je rizik od krvarenja iz sluznica bio veći (tkiva koja oblažu tjelesne šupljine, primjerice nos, probavni sustav i vaginu), Odbor smatra da se rizik može kontrolirati primjenom odgovarajućih mjera.
English: It is used in patients who have one or more risk factors, such as having had a previous stroke, high blood pressure, diabetes, heart failure or being 75 years old or over;
Croatian: Koristi se u bolesnika s jednim ili više čimbenika rizika, kao što je prethodna epizoda moždanog udara, visoki krvni tlak, dijabetes, zatajenje srca ili dob od 75 godina ili starija;
English: The main measure of effectiveness was the number of patients who had another episode of DVT or pulmonary embolism during the study period.
Croatian: Glavna mjera djelotvornosti bio je broj bolesnika koji su imali drugu epizodu DVT-a ili plućne embolije tijekom razdoblja ispitivanja.
English: Treatment is continued while the benefit outweighs the risk of bleeding, which depends on the condition being treated and any existing risk factors.
Croatian: Liječenje se nastavlja sve dok je korist od lijeka veća od rizika od krvarenja, što ovisi o stanju koje se liječi i postojećim čimbenicima rizika.
English: Why is Roteas approved?
Croatian: Zašto je lijek Roteas odobren?
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Roteas's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Roteas nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za primjenu u Europskoj uniji.
English: With respect to safety, overall the risk of serious bleeding such as bleeding into the brain was reduced compared with warfarin, although there may be less difference where warfarin treatment is well managed.
Croatian: S obzirom na sigurnost, ukupni rizik od ozbiljnog krvarenja kao što je krvarenje u mozak smanjen je u usporedbi s liječenjem varfarinom, iako ta razlika može biti manja u slučajevima kada je liječenje varfarinom dobro kontrolirano.
English: It is not intended to provide practical advice on how to use Roteas.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Roteas.
English: The company that markets Roteas will provide educational materials for doctors prescribing the medicine and an alert card for patients, explaining the risks of bleeding with the medicine and how to manage them.
Croatian: Tvrtka koja lijek Roteas stavlja u promet osigurat će edukacijske materijale za liječnike koji propisuju lijek i karticu s upozorenjima za bolesnike, u kojima su objašnjeni rizici od krvarenja pri uporabi lijeka i načini njegove kontrole.
English: What are the risks associated with Roteas?
Croatian: Koji su rizici povezani s lijekom Roteas?
English: • to prevent stroke (caused by blood clots in the brain) and systemic embolism (blood clots in other organs) in patients with non-valvular atrial fibrillation (irregular rapid contractions of the upper chambers of the heart).
Croatian: • za sprječavanje moždanog udara (izazvanog krvnim ugrušcima u mozgu) i sustavne embolije (krvni ugrušci u drugim organima) u bolesnika s nevalvularnom fibrilacijom atrija (nepravilne brze kontrakcije gornjih srčanih šupljina).
English: Roteas must not be used in patients who are actively bleeding, have liver diseases that affect blood clotting, have severe uncontrolled high blood pressure or who have a condition putting them at significant risk of major bleeding.
Croatian: Lijek Roteas ne smije se upotrebljavati u bolesnika s aktivnim krvarenjem, bolestima jetre koje utječu na zgrušavanje krvi, nekontroliranim visokim krvnim tlakom ili u bolesnika sa stanjem koje predstavlja veliki rizik od značajnog krvarenja.
English: It will also carry out a study of the effects of the medicine in patients with atrial fibrillation and good kidney function.
Croatian: Tvrtka će provesti i studiju o učincima lijeka na bolesnike s fibrilacijom atrija i dobrom bubrežnom funkcijom.
English: Doses should be halved in patients with moderately or severely reduced kidney function, or low body weight or in those who are also taking certain medicines (known as P-gp inhibitors) that can interfere with the removal of edoxaban from the body.
Croatian: Doze je potrebno prepoloviti u bolesnika s umjereno do značajno smanjenom bubrežnom funkcijom, niskom tjelesnom težinom ili u bolesnika koji istovremeno uzimaju određene lijekove (poznatiji kao P-gp inhibitori) koji mogu ometati uklanjanje edoksabana iz tijela.
English: When another recommended definition of the type of stroke was used, embolism or stroke due to blood clots was seen in 143 patients given Roteas (0.9%) and 157 given warfarin (1%).
Croatian: Kada je korištena druga preporučena definicija vrste moždanog udara, embolija ili moždani udar izazvani krvnim ugrušcima primijećeni su u 143 bolesnika koji su primali lijek Roteas (0,9 %) i 157 koji su primali varfarin (1 %).
English: Dose adjustments may also need to be made in patients who are switched between Roteas and other anticoagulant medicines.
Croatian: Prilagodba doze možda će biti potrebna i u bolesnika koji s lijeka Roteas prelaze na druge antikoagulanse i obrnuto.
English: By blocking factor Xa, the medicine reduces the levels of thrombin in the blood, which helps treat clots and reduce the risk of them forming in the arteries and veins and leading to DVT, pulmonary embolism, stroke or other organ damage.
Croatian: Blokiranjem faktora Xa, lijek smanjuje razinu trombina u krvi i tako pomaže u liječenju ugrušaka i smanjuje rizik od njihova nastanka u arterijama i venama, što uzrokuje DVT, plućnu emboliju, moždani udar ili oštećenja ostalih organa.
English: For more information about treatment with Roteas, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Roteas pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svojem liječniku ili ljekarniku.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Roteas have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Roteas nalaze se i u sažetku opisa svojstava i uputi o lijeku.
English: The active substance in Roteas, edoxaban, is a ‘factor Xa inhibitor'.
Croatian: Djelatna tvar lijeka Roteas, edoksaban, inhibitor je faktora Xa.
English: Other common side effects are anaemia (low levels of red blood cells), rash and abnormal results in tests of liver function.
Croatian: Druge česte nuspojave uključuju anemiju (niska razina crvenih krvnih stanica), osip i poremećaje jetrene funkcije koji su se pokazali testiranjem.
English: In the treatment and prevention of blood clots in patients with DVT or pulmonary embolism, Roteas was also found to be as effective as warfarin, in a study involving over 8,200 patients.
Croatian: U liječenju i sprječavanju krvnih ugrušaka u bolesnika s DVT-om ili plućnom embolijom, lijek Roteas se u ispitivanju koje je obuhvaćalo više od 8 200 bolesnika pokazao jednako djelotvornim kao varfarin.
English: What benefits of Roteas have been shown in studies?
Croatian: Koje su koristi od lijeka Roteas dokazane u ispitivanjima?
English: A first systemic embolism or stroke occurred in 182 patients given standard doses of Roteas and in 232 of those given warfarin, corresponding to annual rates for these events of around 1.2% and 1.5% respectively.
Croatian: Prva sustavna embolija ili moždani udar dogodili su se u 182 bolesnika koji su primali standardne doze lijeka Roteas i u 232 bolesnika koji su primali varfarin, što godišnje iznosi približno 1,2 %, odnosno 1,5 %.
English: The main measure of effectiveness was the rate of stroke or systemic embolism among the patients each year.
Croatian: Glavni pokazatelj djelotvornosti bio je godišnji postotak moždanog udara ili sustavne embolije među bolesnicima.
English: The most common side effects with Roteas (which may affect up to 1 in 10 people) are bleeding from skin and soft tissues, nose (epistaxis) and the vagina.
Croatian: Najčešće nuspojave lijeka Roteas (koje se mogu javiti u manje od 1 na 10 osoba) su krvarenje iz kože i mekog tkiva, nosno krvarenje (epistaksa) te vaginalno krvarenje.
English: • to treat deep-vein thrombosis (DVT, a blood clot in a deep vein, usually in the leg) and pulmonary embolism (a clot in a blood vessel supplying the lungs), and to prevent DVT and pulmonary embolism from re-occurring.
Croatian: • za liječenje duboke venske tromboze (DVT, krvni ugrušak u dubokoj veni, najčešće u nozi) i plućne embolije (krvni ugrušak u krvnoj žili koja opskrbljuje pluća) te za sprječavanje ponavljanja tih stanja.
English: For practical information about using Roteas, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Roteas bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svojem liječniku ili ljekarniku.
English: There was a trend for better results in patients with reduced kidney function than those whose kidney function was normal.
Croatian: Bolji rezultati primijećeni su kod bolesnika sa smanjenom bubrežnom funkcijom nego kod bolesnika s normalnom bubrežnom funkcijom.
English: The medicine has been shown to be at least as effective as warfarin in reducing stroke rates in patients with atrial fibrillation and in preventing further episodes of DVT or pulmonary embolism.
Croatian: Dokazano je da je lijek u najmanju ruku jednako djelotvoran kao varfarin u smanjenju stope moždanog udara u bolesnika s fibrilacijom atrija te u sprječavanju daljnjih epizoda DVT-a ili plućne embolije.
English: Roteas contains the active substance edoxaban.
Croatian: Roteas sadrži djelatnu tvar edoksaban.
English: How is Roteas used?
Croatian: Kako se Roteas koristi?
English: Roteas has been shown to be as effective as the standard anticoagulant warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation.
Croatian: Dokazano je da je lijek Roteas jednako učinkovit u sprječavanju moždanog udara i sustavne embolije u bolesnika s fibrilacijom atrija kao i uobičajeni antikoagulans varfarin.
English: How does Roteas work?
Croatian: Kako djeluje Roteas?
English: For the full list of all side effects reported with Roteas, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Roteas potražite u uputi o lijeku.
English: Roteas edoxaban
Croatian: Roteas edoksaban
English: Very rare, not known*
Croatian: Vrlo rijetko, Nepoznato*
English: The median follow-up for both groups was 359 days.
Croatian: Medijan praćenja u obje skupine je bio 359 dana.
English: Ask your pharmacist how to throw away you no longer use.
Croatian: Pitajte svog ljekarnika kako baciti lijekove koje više ne koristite.
English: Cmax occurs approximately 30 to 60 minutes after dosing.
Croatian: Cmax postiže se otprilike 30 do 60 minuta nakon doziranja.
English: Do not stop the treatment unless your doctor tells you so.
Croatian: Ne prekidajte liječenje osim ako Vam to ne savjetuje liječnik.
English: Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including medicines obtained without a prescription.
Croatian: Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove, uključujući i one koje ste nabavili bez recepta.
English: In addition, your doctor may identify changes in your blood or urine test results.
Croatian: Dodatno, Vaš liječnik može naći promjene u rezultatima pretraga krvi ili urina.
English: may be taken with or without food.
Croatian: Može se uzimati uz obrok ili bez obroka.
English: No special requirements for disposal.
Croatian: Nema posebnih zahtjeva.
English: None of these analyses were adequately sized to detect differences in outcome in poor metabolisers.
Croatian: Niti jedna od ovih analiza nije bila odgovarajuće veličine za otkrivanje razlika u ishodu za slabe metabolizatore.
English: The patient population included 41.8 % women.
Croatian: Populacija bolesnika uključivala je 41,8% žena.
English: Atrial fibrillation
Croatian: Fibrilacija atrija
English: Children and adolescents Do not give this medicine to children because it does not work.
Croatian: Nemojte davati ovaj lijek djeci jer ne djeluje.
English: Patients were treated for up to 5 years.
Croatian: Bolesnici su bili liječeni do 5 godina.
English: Esomeprazole is expected to give a similar interaction with clopidogrel.
Croatian: Za esomeprazol se očekuje da ima sličnu interakciju s klopidogrelom.
English: Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).
Croatian: Ispitivanja na životinjama ne ukazuju na izravne ili neizravne štetne učinke vezane za trudnoću, embrionalni/fetalni razvoj, porođaj ili postnatalni razvoj (vidjeti dio 5.3).
English: The requirements for submission of (PSURs) reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Croatian: Zahtjevi za podnošenje PSUR-eva za ovaj lijek definirani su u referentnom popisu datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EZ i svim sljedećim ažuriranim verzijama objavljenima na europskom internetskom portalu za lijekove.
English: Medicinal products associated with bleeding risk: There is an increased risk of bleeding due to the potential additive effect.
Croatian: Lijekovi povezani s rizikom od krvarenja: Povećan je rizik od krvarenja zbog mogućeg aditivnog učinka.
English: TOPIC and TROPICAL-ACS were designed to study how to mitigate the bleeding events while maintaining efficacy.
Croatian: TOPIC i TROPICAL-ACS dizajnirane su da ispitaju kako smanjiti događaje krvarenja, a istovremeno zadržati djelotvornost lijeka.
English: The mean CHADS2 score was 2.0 (range 0-6).
Croatian: Srednja vrijednost CHADS2 iznosila je 2,0 (raspon 0-6).
English: • Adults and elderly
Croatian: Doziranje - Odrasli i stariji
English: The ACTIVE-A study included patients who could not receive VKA therapy because they were unable or unwilling to receive the treatment.
Croatian: Studija ACTIVE-A uključivala je bolesnike koji nisu mogli primati VKA terapiju, zbog toga što nisu bili podobni ili nisu željeli primati terapiju.
English: An occasional use of acetylsalicylic acid (no more than 1000 mg in any 24 hour period), should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor.
Croatian: Povremeno uzimanje acetilsalicilatne kiseline (ne više od 1000 mg u 24 sata) općenito ne izaziva probleme, ali o produljenom uzimanju u drugim okolnostima morate razgovarati s liječnikom.
English: Secondary prevention of atherothrombotic events Clopidogrel is indicated in:
Croatian: Sekundarna prevencija aterotrombotičkih događaja Klopidogrel je indiciran u:
English: 9/l); requirement for clopidogrel or oral anticoagulants (OAC); or intolerance to any of the two compounds.
Croatian: 9/l), potreba za klopidogrelom ili oralnim antikoagulansima ili netolerancija prema bilo kojoj od dvije djelatne tvari.
English: Since the CAPRIE trial was not powered to evaluate efficacy of individual subgroups, it is not clear whether the differences in relative risk reduction across qualifying conditions are real, or a result of chance.
Croatian: Kako kliničko ispitivanje CAPRIE nije za cilj imalo procijeniti djelotvornost u pojedinačnim podskupinama, nije jasno jesu li razlike relativnog smanjenja rizika unutar podskupina stvarne ili su slučajan rezultat.
English: Date of first authorisation: 21 September 2009 Date of latest renewal: 3 June 2014
Croatian: Datum posljednje obnove odobrenja: 03. lipnja 2014.